HIV Stigma, HIV status disclosure, and ART adherence in the context of an integrated opioid use disorder and HIV treatment setting in Dar es Salaam, Tanzania

Haneefa T. Saleem, Deja Knight, Cui Yang, Michael Kidorf, Carl Latkin, Iddi Haruna Nkya

Research output: Contribution to journalArticlepeer-review

Abstract

Little is known about social factors, including stigma, that affect antiretroviral therapy (ART) adherence among people enrolled in opioid use disorder treatment (OUDT) in the context of integrated OUDT and HIV treatment models. We qualitatively examined the relationship between HIV stigma, HIV status disclosure, and ART adherence among clients living with HIV at an OUDT clinic with integrated HIV services in Tanzania. We conducted in-depth interviews with 25 clients receiving HIV care at an OUDT clinic in Dar es Salaam, Tanzania between January and April 2020. HIV stigma, particularly anticipated stigma, and HIV status disclosure were key factors that affected ART adherence. Participants feared non-voluntary HIV status disclosure to and HIV stigma from their peers enrolled in OUDT. Most participants reported concealing their HIV status from peers at the OUDT clinic and not associating with other clients living with HIV at the clinic. Reducing HIV stigma and enhancing clinic structures and procedures to maintain privacy and confidentiality are essential to mitigating the effects of stigma on ART adherence.

Original languageEnglish (US)
Pages (from-to)91-94
Number of pages4
JournalAIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
Volume35
Issue number1
DOIs
StatePublished - 2023

Keywords

  • ART adherence
  • HIV status disclosure
  • HIV stigma
  • opioid use disorder treatment
  • social networks

ASJC Scopus subject areas

  • Health(social science)
  • Public Health, Environmental and Occupational Health
  • Social Psychology

Fingerprint

Dive into the research topics of 'HIV Stigma, HIV status disclosure, and ART adherence in the context of an integrated opioid use disorder and HIV treatment setting in Dar es Salaam, Tanzania'. Together they form a unique fingerprint.

Cite this